Casirivimab and imdevimab - Covid-19

You are here : Home > Formulary Search > Casirivimab and imdevimab - Covid-19

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary

Formulations :

Not Specified

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

NFD1

Restrictions / Comments :

Important

Not recommended under NICE TA878

Documentation

Evidence Review

NICE TA878 CMDU APC briefing paper Jun-23.doc

Webpage

NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

PAD Profile

ChemicalSubstance :

Casirivimab and imdevimab

Indication :

Covid-19

Group Name :

Keywords :

CMDU, covid medicines delivery unit, Covid 19, coronavirus, neutralising monoclonal antibodies, antibody, nMABs

Brand Names Include :

Ronapreve

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Casirivimab and imdevimab is used to treat.

No records returned.

Other Drugs

Below are listed other drugs that are used to treat Covid-19.

Committee Recommendations (1)

05 Jul 23 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartland Integrated Care System Area Prescribing Committee agree implementation of NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19.

Casirivimab plus imdevimab is agreed as NON-FORMULARY – Not recommended by NICE